James D Clark

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4694142/james-d-clark-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47 papers	4,597 citations	27 h-index	48 g-index
48 ext. papers	5,073 ext. citations	9.2 avg, IF	4.72 L-index

#	Paper	IF	Citations
47	Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. *Scientific Reports*, **2020**, 10, 8974	4.9	4
46	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. *Journal of Investigative Dermatology*, **2020**, 140, 1546-1555.e4	4.3	21
45	Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. *Bioorganic and Medicinal Chemistry*, **2020**, 28, 115481	3.4	3
44	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2020**, 63, 13561-13577	8.3	19
43	Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. *Arthritis and Rheumatology*, **2019**, 71, 685-695	9.5	21
42	Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. *Clinical Immunology* , **2018**, 191, 10-20	9	15
41	Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.	8.3	57
40	Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). *Journal of Medicinal Chemistry*, **2018**, 61, 8597-8612	8.3	54
39	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. *ACS Chemical Biology*, **2016**, 11, 3442-3451	4.9	85
38	Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. *Journal of Allergy and Clinical Immunology*, **2016**, 137, 1079-1090	11.5	89
37	Parsing the Interferon Transcriptional Network and Its Disease Associations. *Cell*, **2016**, 164, 564-78	56.2	151
36	Network pharmacology of JAK inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 9852-7	11.5	44
35	The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. *Clinical and Experimental Rheumatology*, **2016**, 34, 318-28	2.2	155
34	Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. *Journal of Medicinal Chemistry*, **2014**, 57, 5023-38	8.3	313
33	The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls. *Genome Medicine*, **2012**, 4, 2	14.4	20
32	Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations. *Journal of Rheumatology*, **2012**, 39, 1509-16	4.1	21
31	Preclinical evaluation of an inhibitor of cytosolic phospholipase A2 for the treatment of asthma. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 656-65	4.7	26

30	The expression of splice forms for the rheumatoid arthritis risk associated gene PTPN22 is significantly different for patients compared to controls. *Annals of the Rheumatic Diseases*, **2012**, 71, A56.1-A56	2.4	
29	The cPLA2 inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. *Neuropharmacology*, **2011**, 60, 633-41	5.5	4
28	Cytosolic phospholipase A2 blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs. *Journal of Immunology*, **2011**, 187, 1986-97	5.3	10
27	Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis. *American Journal of Veterinary Research*, **2011**, 72, 757-63	1.1	7
26	A human CXCL13-induced actin polymerization assay measured by fluorescence plate reader. *Assay and Drug Development Technologies*, **2010**, 8, 73-84	2.1	5
25	Utility of cytosolic phospholipase A2 (cPLA2) inhibitors in the treatment of asthma. *Progress in Respiratory Research*, **2010**, 207-212		
24	Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. *Arthritis and Rheumatism*, **2010**, 62, 2283-93		68
23	Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 4383-405	3.4	26
22	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 1156-71	8.3	12
21	Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. *Journal of Neuroimmunology*, **2008**, 204, 29-37	3.5	53
20	Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. *Journal of Medicinal Chemistry*, **2008**, 51, 3388-413	8.3	70
19	Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 1345-58	3.4	29
18	Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors. *Analytical Biochemistry*, **2008**, 383, 217-25	3.1	7
17	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. *Journal of Biological Chemistry*, **2007**, 282, 33295-33304	5.4	66
16	Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. *Journal of Medicinal Chemistry*, **2007**, 50, 1380-400	8.3	70
15	Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization. *Journal of Medicinal Chemistry*, **2006**, 49, 135-58	8.3	61
14	1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2alpha inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 2978-81	2.9	17
13	A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. *Analytical Biochemistry*, **2005**, 343, 143-51	3.1	48

12	Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. *Journal of Experimental Medicine*, **2005**, 202, 841-51	16.6	120
11	Potential therapeutic uses of phospholipase A2 inhibitors. *Expert Opinion on Therapeutic Patents*, **2004**, 14, 937-950	6.8	27
10	Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 4501-4	2.9	20
9	Cytosolic phospholipase A2alpha-deficient mice are resistant to collagen-induced arthritis. *Journal of Experimental Medicine*, **2003**, 197, 1297-302	16.6	129
8	Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. *Cell*, **1999**, 97, 349-60	56.2	304
7	Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A(2): structure-function studies with vesicle, micelle, and membrane assays. *Biochimica Et Biophysica Acta - Biomembranes*, **1999**, 1420, 45-56	3.8	63
6	Characterization of Ca2+-dependent phospholipase A2 activity during zebrafish embryogenesis. *Journal of Biological Chemistry*, **1999**, 274, 19338-46	5.4	49
5	Solution structure and membrane interactions of the C2 domain of cytosolic phospholipase A2. *Journal of Molecular Biology*, **1998**, 280, 485-500	6.5	109
4	Independent folding and ligand specificity of the C2 calcium-dependent lipid binding domain of cytosolic phospholipase A2. *Journal of Biological Chemistry*, **1998**, 273, 1365-72	5.4	101
3	Cytosolic phospholipase A2. *Journal of Lipid Mediators and Cell Signalling*, **1995**, 12, 83-117		432
2	A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. *Cell*, **1991**, 65, 1043-51	56.2	1552
1	Malate synthase: proof of a stepwise Claisen condensation using the double-isotope fractionation test. *Biochemistry*, **1988**, 27, 5961-71	3.2	40